Nasdaq

QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing

QuidelOrtho Corporation QDEL recently announced the FDA 510(k) clearance for its QuickVue COVID-19 test.With CLIA certificates of waiver, this approval permits the test to be used accurately and ...
Nasdaq

QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

Designed for symptomatic individuals within six days of symptom onset, the QuickVue COVID-19 test is cleared for use in individuals aged 14 or older when self-testing, and in those aged two and older ...
Business Wire

Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...
Morningstar

QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of ...
Reuters

Flu tests miss many cases, U.S. CDC confirms

WASHINGTON, Aug 6 (Reuters) - Current quick tests for flu miss many cases of the new pandemic H1N1 strain, researchers at the U.S. Centers for Disease Control and Prevention reported on Thursday. Sign ...